Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1
Open Access
- 27 April 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (27) , 44255-44265
Abstract
Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1 Structure Based Discovery of Clomifene as a Potent Inhibitor of Cancer-Associated Mutant IDH1Keywords
This publication has 26 references indexed in Scilit:
- Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoACS Medicinal Chemistry Letters, 2012
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursThe Journal of Pathology, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agentsFertility and Sterility, 2010
- Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132HCell Research, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammationInternational Journal of Experimental Pathology, 2000
- Development, pharmacology and clinical experience with clomiphene citrateHuman Reproduction Update, 1996
- Clomiphene citrate for ovulation induction in women with oligo-amenorrhoeaCochrane Database of Systematic Reviews, 1996